Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China

Reuters

Jan 31

Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China

Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, New Jersey, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE75305) on January 30, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2607028382"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607028382\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607028382?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-31 01:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607028382","market":"us","top_or_hot":-1,"title":"Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE75305) on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nFrontage Holdings Expands Early Phase Clinical Research Capabilities in US and China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-31 01:01</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, <a href=\"https://laohu8.com/S/NJR\">New Jersey</a>, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE75305) on January 30, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0028","symbol_name":"国家队","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL9Q5dc3:1","article_id":"2607028382","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607028382","pubTimestamp":1769792462,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, New Jersey, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, in","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"300347":"泰格医药","BK0028":"国家队","BK1141":"生命科学工具和服务","BK1583":"高瓴概念","BK1576":"医药外包概念","BK0216":"研究试验","LU1146622755.USD":"安本中国A股股票基金A Acc","BK0077":"质押式回购","BK0174":"增持","01521":"方达控股","LU1820825898.SGD":"Aberdeen Standard SICAV I - China A Share Equity A Acc SGD-H"},"translate_title":"方达控股扩大在美国和中国的早期临床研究能力","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"300347":0.9,"01521":0.9},"content_text":"Frontage Holdings Expands Early Phase Clinical Research Capabilities in US and China\n    \n\n        Frontage Holdings Corporation, through its subsidiary Frontage Laboratories, has expanded its early phase clinical research capabilities in both the United States and China. This strategic investment enhances support for pharmaceutical and biotech partners, particularly in managing high-volume bioequivalence programs and enabling multi-regional clinical trial execution. The expansion includes a modern 160-bed Phase I clinical unit in Secaucus, New Jersey, and strengthened radiolabeled human AME research capabilities. Additionally, Frontage is increasing its presence in Oncology Phase I trials through new partnerships with hospitals and clinical networks, further broadening its global clinical development solutions.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Frontage Holdings Corporation published the original content used to generate this news brief via PR Newswire (Ref. ID: NE75305) on January 30, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}